Study Description: Subjects are being asked to be in this research study who recently completed the TDE-PH-310 study. The purpose of this research study is to assess how an investigational drug called UT-15C (treprostinil diethanolamine also known as treprostinil diolamine) works to treat PA. The study will continue for four years. Subject visits will occur at Baseline, Weeks 6, 12, and every 12weeks thereafter.
Principal Investigator: Clark McDonough
Compensation: Yes, subjects will be compensated.
Compensation Explanation: There is no direct payment for participating in this study. Some payment may be provided for travel related expenses required for study participation (e.g., parking fees).
If you don't see specific studies that interest you, please submit your contact information for future studies.